CEVEC is a biotechnology company specialized in the production of biopharmaceuticals using its proprietary CAP-Technology, a unique human suspension cell-based production platform.
CAP-GT cell lines enable scalable viral gene therapy vector production with easy handling and competitive production costs when compared to adherent cell culture systems. In addition, the Company has developed a helper-free AAV (adeno-associated virus) packaging cell line for scalable stable gene therapy vector production independent of transient transfection or helper virus.
CAP-Go enables the production of recombinant proteins previously out of reach that are notoriously difficult to express in conventional cell lines including blood coagulation factors, C1-Inhibitor and others.
|Field of Activity
||Development and licensing of cell-based production platforms for biopharmaceuticals|
|Ownership Structure and Financing||Privately owned; investors are Peppermint VenturePartners, Creathor Venture, NRW.Bank, KfW Bank, G.A.T. Holding, Investtodate GmbH and several private persons.|
|Partners||Selected license partners: Beckman Research Institute, BioLamina AB, Biotest AG, CellGenix GmbH, CSL Limited, Généthon, medac, PlasmidFactory GmbH & Co. KG and Provecs Medical GmbH CDMO partners: Paragon Bioservices Inc. and GenIbet Biopharmaceuticals|
|Technology and Unique Selling Point||CEVEC´s human suspension cell-based CAP technology provides fully scalable, clinical-grade good manufacturing practice (GMP) compatible solutions for the production of viral gene therapy vectors and recombinant glycoproteins. The CAP-GT platform includes a helperfree AAV packaging cell line for stable vector production and RCA-free production of adenoviral vectors for gene therapy applications. The CAP-Go system provides outstanding pharmacokinetic profi les and characteristics in terms of authentic and tailor-made glycosylation capabilities as well as high yield production of complex proteins.|
|Products / Services||Cell line and process development and technology licensing for the pro duction of tailor-made recombinant glycoproteins and gene therapy vectors.|
|Membership in networks / associations||BioRiver, Bio Cologne, Bio Deutschland, BIOCOM, Dechema, VCI|
|Date of Incorporation / Number of Employees||2003 / 30 employees|
|Telephone||+49 221 460 208-00|
|Telefax||+49 221 460 208-01|
CEVEC Pharmaceuticals GmbH